News
Sanofi's riliprubart gets FDA orphan drug status for organ transplant rejection, unlocking key development perks.
Zacks Investment Research on MSN21h
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?ADMA Biologics ADMA and Takeda TAK are leading players in the plasma derived immunoglobulin sector. ADMA markets ...
The European Commission (EC) has approved argenx’s Vyvgart (efgartigimod alfa) subcutaneous (SC) injection to treat chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback